Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Direkt zur Navigaton springen.
Direkt zum Inhalt springen.

Navigation/Suche

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Biersack, HJ; Palmedo, H; Andris, A; Rogenhofer, S; Knapp, FF; Guhlke, S; Ezziddin, S; Bucerius, J; von Mallek, D.
Palliation and Survival After Repeated ¹⁸⁸Re-HEDP Therapy of Hormone-Refractory Bone Metastases of Prostate Cancer: A Retrospective Analysis
J NUCL MED. 2011; 52(11): 1721-1726. Doi: 10.2967/jnumed.111.093674
Web of Science PubMed FullText FullText_MUG

Co-Autor*innen der Med Uni Graz: Bucerius Jan Alexander
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: This retrospective study compared the effects of single and multiple administrations of Re-186-hydroxyethylidenediphosphonate (Re-186-HEDP) on palliation and survival of prostate cancer patients presenting with more than 5 skeletal metastases. Methods: A total of 60 patients were divided into 3 groups. Group A (n = 19) consisted of patients who had received a single injection; group B (n = 19), patients who had 2 injections; and group C (n = 22), patients who had 3 or more successive injections. The Re-188-HEDP was prepared using non-carrier-added Re-188 obtained from an in-house W-188/Re-188 generator after dilution with carrier perrhenate. Patients' data available from the referring physicians-including prostate-specific antigen levels-were entered into a Windows-based matrix and analyzed using a statistical program. The Gleason scores were similar for all 3 groups. Results: Mean survival from the start of treatment was 4.50 +/- 0.81 mo (95% confidence interval [CI], 2.92-6.08) for group A, 9.98 +/- 2.21 mo (95% CI, 5.65-14.31) for group B, and 15.66 +/- 3.23 (95% CI, 9.33-22.0) for group C. Although the 3 groups did not differ in Gleason score, the number of lost life-years was significantly lower in group C than in groups A and B. Pain palliation was achieved in 89.5% of group A, 94.7% of group B, and 90.9% of group C. Conclusion: Post-treatment overall survival could be improved from 4.50 to 15.66 mo by multiple-injection bone-targeted therapy with Re-188-HEDP, when compared with a single injection. Significant pain palliation was common and independent of administration frequency.
Find related publications in this database (Keywords): Re-188-HEDP; bone metastases; palliation; prostate cancer; survival